A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Psoriatic disease is a long-term (chronic) disease with, thus far, no known cure. The good news, however, is that there are ...

The European Medicines Agency’s human medicines committee (CHMP) adopted positive opinions for six biosimilar medicines at its June meeting.

The following six biosimilars were given a positive opinion at the June meeting: treatments for treatment of age-related macular degeneration and visual impairment: Mynzepli (aflibercept), and its ...

Cimzia (certolizumab) is a prescription drug used to treat plaque psoriasis, Crohn’s disease, and some types of arthritis, including rheumatoid arthritis. It’s given as an injection under the ...

Bio-Thera receives positive CHMP opinion for Usymro, a biosimilar referencing Stelara: Guangzhou, China Monday, June 23, 2025, 15:00 Hrs [IST] Bio-Thera Solutions Inc., a commerci ...

The FDA approved a new presentation of Steqeyma®, for the treatment of pediatric patients with plaque psoriasis or psoriatic arthritis.

Dr. Michael Garshick discusses recently published recommendations for cardiovascular risk screening for patients with ...

Deucravacitinib met its primary endpoint of more than 20% improvement in ACR20 response among patients with psoriatic ...

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients ...

Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes. This study sought to explore the syndrome's role in a more precisely ...

A large PsA cohort study found metabolic syndrome linked to spine and enthesis degeneration, but not to radiographic joint ...